|
Originally published In Press as doi:10.1074/jbc.M002844200 on August 7, 2000
J. Biol. Chem., Vol. 275, Issue 44, 34528-34533, November 3, 2000
-Adrenergic Pathway Induces Apoptosis through Calcineurin
Activation in Cardiac Myocytes*
Shuichi
Saito,
Yukio
Hiroi,
Yunzeng
Zou,
Ryuichi
Aikawa,
Haruhiro
Toko,
Futoshi
Shibasaki ,
Yoshio
Yazaki,
Ryozo
Nagai, and
Issei
Komuro§
From the Department of Cardiovascular Medicine, University of Tokyo
Graduate School of Medicine, Tokyo 113-8655, Japan and the
Tokyo Metropolitan Institute of Medical Science,
Tokyo 113-8613, Japan
Received for publication, April 3, 2000, and in revised form, July 31, 2000
 |
ABSTRACT |
Apoptosis of cardiac myocytes is one of the
causes of heart failure. Here we examine the mechanism by which the
activation of -adrenergic receptor induces cardiomyocyte apoptosis.
Terminal deoxynucleotide transferase-mediated dUTP nick end
labeling and DNA ladder analyses revealed that isoproterenol (Iso)
induced the apoptosis of cardiac myocytes of neonatal rats through an increase in intracellular Ca2+ levels. The
Iso-induced cardiomyocyte apoptosis was strongly inhibited by the
L-type Ca2+ channel antagonist nifedipine and by the
calcineurin inhibitors cyclosporin A and FK506. Iso reduced the
phosphorylation levels of the proapoptotic Bcl-2 family protein Bad and
induced cytochrome c release from mitochondria to the
cytosol through calcineurin activation. Infusion of Iso increased
calcineurin activity by ~3-fold in the hearts of wild-type mice but
not in the hearts of transgenic mice that overexpress dominant negative
mutants of calcineurin. Terminal deoxynucleotide transferase-mediated dUTP nick end labeling analysis revealed that infusion of Iso induced
apoptosis of cardiac myocytes and that the number of apoptotic cardiomyocytes was significantly less in the hearts of the transgenic mice compared with the wild-type mice. These results suggest that calcineurin plays a critical role in Iso-induced apoptosis of cardiac
myocytes, possibly through dephosphorylating Bad.
 |
INTRODUCTION |
Heart failure is the final clinical manifestation of a variety of
human heart diseases, including idiopathic dilated cardiomyopathy, hypertrophic cardiomyopathy, and coronary artery disease. In these pathologic conditions, cardiomyocytes undergo apoptosis, and a loss of
cardiomyocytes is postulated to cause heart failure (1-3). However,
the mechanism by which cardiomyocytes fall into apoptosis is still unknown.
Recently, accumulating evidence has suggested that various factors such
as angiotensin II, tumor necrosis factor- , and oxidative stress
induce apoptosis of cardiac myocytes (4-6). An adrenergic receptor
agonist, norepinephrine, has been reported to be elevated in the plasma
of heart failure patients (7) and to induce cardiomyocyte apoptosis (8,
9). It has recently been reported that isoproterenol (Iso)1 induces apoptosis of
cardiac myocytes in vivo through -adrenergic receptors
(10) and that norepinephrine-induced cardiomyocyte apoptosis is
suppressed by protein kinase A inhibitors (8-10). Selective
overexpression of heterotrimeric GTP-binding proteins , which
transmit signals from -adrenergic receptors to adenylyl cyclase, has
also been reported to induce cardiomyocyte apoptosis in transgenic mice
hearts (11). These results suggest that activation of protein kinase A
through -adrenergic receptors induces apoptosis of cardiac myocytes
during the development of heart failure. Activation of -adrenergic
receptors increases intracellular Ca2+ levels through
voltage-dependent Ca2+ channels. Elevation of
cytosolic Ca2+ has been reported to induce apoptosis in
some cell types through activation of a
Ca2+-dependent phosphatase calcineurin
(12-14). Although calcineurin has recently attracted a great attention
as a novel regulator of cardiomyocyte hypertrophy (15), it remains
unknown whether calcineurin is involved in -adrenergic
stimulation-induced cardiomyocyte apoptosis.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Iso and nifedipine were obtained from
Sigma, ionomycin was from Calbiochem, and cyclosporin A was from
Wako Chemical Industries, Ltd. (Osaka, Japan). FK506 was the kind gift
of Fujisawa Pharmaceutical Co., Ltd. (Osaka, Japan). Anti-Bad and
anti-phosphospecific-Bad(serine 136) antibodies were purchased from New
England Biolabs, Inc. (Beverly, MA). Anti-Bcl-2 and anti-Bcl-xL
monoclonal antibodies were from Transduction Laboratories (Lexington,
KY), and anti cytochrome c polyclonal antibody was from
Santa Cruz Biotechnology, Inc.
Cell Culture--
Primary cultures of cardiac myocytes were
prepared from the ventricles of 1-day-old Wistar rats as described
previously (16). Cardiomyocytes were plated onto 60-mm plastic culture
dishes at a field density of 1 × 105
cells/cm2 and cultured in Dulbecco's modified Eagle's
medium with 10% fetal calf serum. Immunocytochemical study revealed
that more than 90% of cells were cardiac myocytes.
Terminal Deoxynucleotide Transferase-mediated dUTP Nick End
Labeling (TUNEL)--
Cardiomyocytes plated on a cover glass were
fixed with 4% paraformaldehyde solution for 30 min at room
temperature. After a rinse with phosphate-buffered saline, the samples
were first incubated with phalloidin-rhodamine for 1 h and with
TUNEL reaction mixture containing terminal deoxynucleotidyl transferase
and fluorescein isothiocyanate-dUTP. In tissues, the 3-µm thick
paraffin sections were deparaffinized by immersing in xylene,
rehydrated, and incubated in phosphate-buffered saline with 2%
H2O2 to inactivate endogenous peroxidases.
Next, the sections were incubated with proteinase K (20 µg/ml),
washed in phosphate-buffered saline, and incubated with terminal
deoxynucleotidyl transferase for 90 min and fluorescein isothiocyanate-dUTP for 30 min at 37 °C using an apoptosis detection kit (Takara Biomedical). The sections were stained with diaminobenzine for 10 min at room temperature, washed in phosphate-buffered saline, and mounted for light microscopic observations. The number of TUNEL-positive cardiac myocytes was determined by counting 3 × 105 cardiac myocytes. All morphometric measurements were
performed by at least two independent individuals in a blinded manner.
Agarose Gel Electrophoresis for DNA Fragmentation--
Cells
(4 × 105) were lysed in 200 µl of lysis buffer (10 mM Tris-HCl (pH 7.4), 10 mM EDTA, 0.5% Triton
X-100) followed by incubation with 40 µg of RNase (Roche Molecular
Biochemicals) for 1 h at 37 °C and 100 µg of proteinase K
(Roche Molecular Biochemicals) for 1 h at 37 °C, and only
fragmented DNA was extracted. The pellet was resuspended in TE buffer
(10 mM Tris-HCl (pH 7.4), 1 mM EDTA) and
treated with DNase-free RNase (Roche Molecular Biochemicals) for 1 h at 37 °C. DNA was ethanol-precipitated and finally resuspended in
distilled water. The fragmented DNA was electrophoretically fractionated on 1.5% agarose gel and stained with ethidium bromide.
Immunoblotting and Immunoprecipitation--
To detect
phosphorylation of Bad, cells (4 × 105) were lysed in
a buffer (10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA (pH 8.0), 150 mM NaCl, 1% Triton
X-100, 0.2 mM sodium ortho-vanadate, 0.2 mM phenylmethylsulfonyl fluoride, 0.5% Nonidet P-40), and Bad was immunoprecipitated with anti-Bad antibody. Immunoprecipitates were recovered with protein A-agarose, separated by 15%
SDS-polyacrylamide gel electrophoresis, and immunoblotted with
anti-phosphospecific-Bad (Ser-136) antibody (New England Biolabs).
Total Bad content was assessed using anti-Bad monoclonal antibody.
To detect cytochrome c, cells were suspended in a buffer (20 mM HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride) for 3 min on ice,
homogenized by 10 strokes in a Dounce homogenizer, and centrifuged at
15,000 rpm for 15 min. The supernatant was the cytosol fraction, and
the pellet was resolved in lysis buffer as the membrane fraction.
Generation of Dominant Negative (dn) Calcineurin Transgenic
Mice--
A cDNA encoding human calcineurin A (CnA) was obtained
from a T cell gt 10 library using oligonucleotides as hybridization probes (12). CnA lacking the autoinhibitory and the calmodulin binding domains was constructed by polymerase chain reaction to introduce a stop codon after N407. The catalytically inactive calcineurin mutant (dn calcineurin) was obtained from CnA by mutating the histidine at position 160, a calcineurin active site, to
glutamine (14). CnA has been reported to prevent Bad redistribution as a trans-dominant negative mutant of CnA induced by an intracellular Ca2+ release agent (14). Hemagglutinin-tagged dn
calcineurin was subcloned into the -myosine heavy chain
promoter-containing expression vector between the lamin A untranslated
region (12) and simian virus 40 poly(A). The linearized DNA was
injected into pronuclei of eggs from BDF1 mice, which were transferred
into the oviducts of pseudopregnant ICR mice. The transgene was
identified by polymerase chain reaction with transgene-specific primers
and by Southern blot analysis using a 32P-labeled simian
virus 40 intron sequence. Two lines of 16-18-week-old dn calcineurin
transgenic mice and wild-type littermate mice were used in the present
study. All protocols were approved by the guidelines of the University
of Tokyo.
Calcineurin Phosphatase Assays--
Determination of the
calcineurin activity of hearts was performed as described previously
(12). Briefly, murine hearts were homogenized in 100 µl of lysis
buffer (50 mM Tris-HCl (pH 7.5), 1 mM EDTA,
0.5% Tween-20, 0.5 mg/ml bovine serum albumin, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin), and after cell debris had been removed by
centrifugation at 10,000 × g for 5 min at 4 °C,
calmodulin-binding calcineurin was separated from calmodulin and
non-calmodulin-binding calcineurin with an ultrafree-MC microcentrifuge
filtertube (100,000 NMWL filter unit; Millipore Co.), and the
supernatant was used for the phosphatase assay. A calcineurin
substrate, glutathione S-transferase-RII peptide,
which was fixed to glutathione-cellulose beads, was first phosphorylated by protein kinase A in the presence of
[ 32P]ATP (12). The 32P-labeled RII
peptide was incubated in the extracts with 50 µl of phosphatase
buffer (100 mM Tris-HCl (pH 7.4), 1 mM
MnCl2, 0.1 mM CaCl2, 0.5 mg/ml
bovine serum albumin, 100 mM calmodulin, 0.5 mM
dithiothreitol) for 30 min at 30 °C. 500 nM okadaic acid
was added to the reactions to suppress endogenous protein phosphatases PP1 and PP2A. Reactions were stopped by adding 500 µl of stop buffer
(10% trichloroacetic acid, 0.1 M sodium phosphate, 10 mg/ml bovine serum albumin). After centrifugation, the released
[32P]phosphate was determined by Cherenkov methods.
Statistical Analysis--
All results are expressed as mean ± S.E. Multiple comparisons among three groups were carried out by
2-way analysis of variance and Fisher's exact test for post
hoc analyses. A value of p < 0.05 was considered
significant statistically.
 |
RESULTS |
Iso Induces Cardiomyocyte Apoptosis through an Increase in
Intracellular Ca2+ Levels--
To elucidate the mechanism
by which -adrenergic stimulation induces cardiomyocyte apoptosis,
cultured cardiac myocytes of neonatal rats were incubated with a
-adrenergic receptor agonist, Iso, and subjected to TUNEL analysis.
Less than 5% of cardiac myocytes were TUNEL-positive in the serum-free
culture condition. Incubation with Iso for 48 h increased
the number of TUNEL-positive cells in a dose-dependent
manner (Fig. 1). A calcium
ionophore, ionomycin (1 µM), which causes
sustained elevation of intracellular Ca2+ concentration,
also increased the number of TUNEL-positive cells (Fig. 1). Many nuclei
of these TUNEL-positive cells were condensed and fragmented (data not
shown), suggesting that Iso induces apoptosis of cardiac myocytes.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 1.
Iso induces cardiomyocyte apoptosis.
Cardiac myocytes were incubated for 48 h with the indicated
concentrations of Iso (0.1-50 µM) or 1 µM ionomycin. The percentage of TUNEL-positive
cardiomyocytes is presented as the average ± S.E. from three
independent experiments. *, p < 0.05 versus
control.
|
|
Iso Induces Cardiomyocyte Apoptosis through the
Ca2+-Calcineurin Pathway--
Activation of -adrenergic
receptors has been reported to increase intracellular Ca2+
levels by increasing Ca2+ influx through
voltage-dependent Ca2+ channels (17, 18). When
cardiomyocytes were treated with the selective L-type Ca2+
channel antagonist nifedipine (1 µM) for 1 h,
Iso-induced cardiomyocyte apoptosis was significantly suppressed (Fig.
2A), suggesting that the
Ca2+ influx through L-type Ca2+ channels plays
a critical role in Iso-induced cardiomyocyte apoptosis. Elevation of
cytosolic Ca2+ has been reported to induce apoptosis in
some cell types through activation of a
Ca2+-dependent phosphatase calcineurin
(12-14). We thus examined whether calcineurin is also involved in
Iso-induced cardiomyocyte apoptosis. Treatment with the calcineurin
inhibitors cyclosporin A (CsA) (1 µM) and FK506 (10 µg/ml) strongly suppressed Iso-induced apoptosis of cardiac myocytes
(Fig. 2, A and B). To confirm the role of calcineurin in Iso-induced apoptosis, we examined DNA fragmentation by
gel electrophoresis. When cardiac myocytes were exposed to Iso (50 µM) for 48 h, extracted genomic DNA showed prominent
ladder formation characteristic of apoptosis. The Iso-induced DNA
ladder formation was almost completely suppressed by treatment with
either CsA or FK506 (Fig. 2C). These results suggest that
the Ca2+-calcineurin pathway plays a critical role in
-adrenergic receptor-induced apoptosis in cardiac myocytes.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 2.
Iso induces cardiomyocyte apoptosis
through the Ca2+-calcineurin dependent pathway.
A, after preincubation with CsA (1 µM), FK506
(10 µg/ml), or nifedipine (1 µM) for 1 h, cardiac
myocytes were stimulated by Iso (50 µM) for 48 h.
The percentage of TUNEL-positive cardiomyocytes shown is from three
independent experiments (mean ± S.E.). *, p < 0.05 versus control. B, after preincubation with
CsA (1 mM) or FK506 (10 mg/ml) for 1 h, cardiac
myocytes were marked by staining with phalloidin-rhodamine
(A, C, E, G). Next, TUNEL
staining was performed using fluorescein isothiocyanate-conjugated dUTP
(B, D, F, H). Shown are
unstimulated cardiomyocytes (A and B),
cardiomyocytes incubated with Iso (50 µM) for 48 h
(C and D), and cardiomyocytes incubated with Iso
(50 mM) for 48 h after pretreatment with CsA (1 µM) (E and F) or FK 506 (10 µg/ml) (G and H) for 1 h. C,
fragmented genomic DNA was isolated from cardiac myocytes. DNA was
separated by electrophoresis in 1.5% agarose gel. Lanes:
1, control; 2, Iso (50 µM);
3, Iso plus CsA (1 µM) pretreatment;
4, Iso plus FK506 (10 µg/ml) pretreatment. bp,
base pairs.
|
|
Iso Dephosphorylates Bad through the Ca2+-Calcineurin
Pathway--
Apoptosis is determined by the relative balance between
proapoptotic molecules such as Bad and Bax and antiapoptotic molecules such as Bcl-2 and Bcl-xL (19-21). Bad promotes cell death by
inhibiting Bcl-2 and Bcl-xL function. Phosphorylation of Bad at Ser-136
by protein kinase B (22) or mitogen-activated protein kinase cascades (21) promotes cell survival. Recently, Ca2+-mobilizing
agents have been reported to dephosphorylate Bad by activating
calcineurin and to enhance Bad heterodimerization with Bcl-xL, leading
to apoptosis (14). We thus examined the role of Bad in Iso-induced
apoptosis of cardiomyocytes. Western blot analysis using
anti-phospho-Bad antibody revealed that Bad was highly phosphorylated
in control cardiac myocytes. Phosphorylation levels of Bad were
transiently reduced at 2 h and 4 h after addition of Iso (50 µM) (Fig. 3A). A
calcium ionophore, ionomycin (1 µM), also decreased
phosphorylation levels of Bad in cardiac myocytes (Fig. 3A).
When the Ca2+ influx and calcineurin activation were
inhibited by treatment with nifedipine (1 µM) and FK506
(10 µg/ml), respectively, Iso-induced dephosphorylation of Bad was
abolished (Fig. 3A). These results suggest that the
Ca2+-calcineurin pathway is necessary for Iso-induced
dephosphorylation of Bad in cardiac myocytes. On the other hand,
expression levels of Bcl-2 and Bcl-xL were not changed by Iso
stimulation (Fig. 3B).

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 3.
Iso dephosphorylates Bad protein through
calcineurin. A, cardiomyocytes were incubated with Iso
(50 µM) or ionomycin (1 µM). Bad was
immunoprecipitated with anti-Bad antibody, subjected to
SDS-polyacrylamide gel electrophoresis, and transferred to
nitrocellulose filters. Blots were subsequently probed with
anti-phosphospecific-Bad antibody (rows 1-4) or
anti-Bad antibody (row 5), followed by ECL-based detection.
Rows: 1 and 5, Iso (50 µM); 2, ionomycin (1 µM);
3, Iso plus FK506 (10 µg/ml) pretreatment; 4,
Iso plus nifedipine (1 µM) pretreatment. Representative
blots of phosphospecific Bad (rows 1-4) and Bad (row
5) from three independent experiments are shown. B,
cardiomyocytes were stimulated by Iso (50 µM) for the
indicated periods of time, and Western blot analysis was performed
using anti-Bcl-2 and -Bcl-xL antibodies. Representative blots of Bcl-2
and Bcl-xL from three independent experiments are shown.
|
|
Iso Induces the Release of Cytochrome c from Mitochondria to the
Cytosol through the Ca2+-Calcineurin Pathway--
A
growing body of evidence indicates that cytochrome c release
from mitochondria to the cytosol, which is tightly regulated by the
Bcl-2 family proteins, induces activation of caspases, leading to
apoptosis (23-25). We thus examined the subcellular distribution of
cytochrome c in cardiomyocytes in the absence or presence of
Iso. In unstimulated cardiomyocytes, cytochrome c existed
abundantly in the membrane fraction and slightly in the cytosol
fraction. From 8 h after exposure to Iso (50 µM), the cytosol fraction of cytochrome c was significantly
increased, and the increase of cytochrome c in the cytosol
continued until 24 h (Fig.
4A). To determine whether
calcineurin is involved in the Iso-induced release of cytochrome
c, the cells were pretreated with CsA (1 µM)
and FK506 (10 µg/ml). Both calcineurin inhibitors strongly reduced
the release of cytochrome c from mitochondria to the cytosol
induced by Iso (Fig. 4B). These results suggest that
calcineurin plays an important role in the Iso-induced release of
cytochrome c from mitochondria to the cytosol in cardiac
myocytes.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 4.
Iso induces the release of cytochrome
c from mitochondria to the cytosol. Immunoblot
analysis was performed using anti-cytochrome c antibody
after separating the cytosol and membrane fractions. A,
cardiomyocytes were treated with Iso (50 µM) for the
indicated periods of time. B, after pretreatment of cardiac
myocytes with CsA (1 µM) and FK506 (10 µg/ml) for
1 h, cardiac myocytes were stimulated by Iso (50 µM)
for 24 h. Representative blots of cytochrome c from
three independent experiments are shown. fr.,
fraction.
|
|
Iso Induces Less Apoptosis in the Hearts of dn Calcineurin
Transgenic Mice--
We further examined the role of calcineurin in
cardiomyocyte apoptosis of in vivo heart using transgenic
mice that overexpress dominant negative mutants of calcineurin (dn
calcineurin). The calcineurin activity was increased ~3-fold by
infusion of Iso (20 mg/kg) in the hearts of wild-type mice but not of
the transgenic mice (Fig. 5A).
We next evaluated Iso-induced cardiomyocyte apoptosis in the heart
using the TUNEL method. There was no TUNEL-positive cardiomyocyte in
the hearts of wild-type mice before infusion of Iso. Infusion of Iso
(20 mg/kg) induced apoptosis of many cardiac myocytes of wild-type mice
(7.2 ± 2.5 of 105 cardiac myocytes) (Fig. 5,
B and C). The number of TUNEL-positive cells was
significantly smaller in the hearts of the transgenic mice (1.5 ± 1.3 of 105 cardiac myocytes) and wild-type mice
administered with FK506 (1 mg/kg/day, intramuscular) for 3 days
(1.3 ± 1.5 105 cardiac myocytes) than in the hearts
of wild-type mice (Fig. 5B). These results suggest that
calcineurin is also involved in -stimulant-induced cardiomyocyte
apoptosis of in vivo heart.

View larger version (78K):
[in this window]
[in a new window]
|
Fig. 5.
Iso induces less apoptosis in the
hearts of dn calcineurin transgenic mice. A, transgenic
mice overexpressing dn calcineurin in the heart were created using the
promoter of the -myosin heavy chain gene. To determine calcineurin
activity, the lysates of murine hearts were subjected to phosphatase
assay using the 32P-labeled RII peptides. Note that Iso
activated calcineurin in the hearts of wild-type mice (wild)
but not in the hearts of dn calcineurin transgenic mice
(Tg). *, p < 0.05 versus control
wild-type mice. B, at 24 h after Iso infusion (20 mg/kg), the number of TUNEL-positive cardiomyocytes was counted and is
presented per 105 cardiomyocyte nuclei. There were
significantly fewer TUNEL-positive cells in the hearts of dn
calcineurin transgenic mice or FK506-administered wild-type mice
(wild+FK506) than in the hearts of wild-type mice. *,
p < 0.05 versus wild-type mice infused with
Iso. C, representative histological sections from the hearts
of Iso-infused transgenic mice. A TUNEL-positive cell is indicated by
an arrow.
|
|
 |
DISCUSSION |
Many lines of evidence have suggested that activation of the
sympathetic nervous system is observed in patients with heart failure
and exerts deleterious effects on human hearts (7, 26, 27). Activation
of the sympathetic nervous system provides the rationale for the use of
-adrenergic receptor antagonists to treat heart failure. In fact,
therapeutic interventions by -adrenergic receptor antagonists not
only improve cardiac contractility but also improve the prognosis of
heart failure (28-30). In the present study, we examined the mechanism
by which -adrenergic stimulation induces injury of cardiomyocytes.
Apoptosis has been demonstrated to occur in the myocardium in a variety
of pathological situations. The number of apoptotic cardiomyocytes is
increased in the myocardium obtained from heart failure patients (1,
2). Furthermore, prominent cardiomyocyte apoptosis was observed in the
hearts of transgenic mice overexpressing GTP-binding proteins
, which transmit signals from -adrenergic receptors to adenylyl
cyclase, and treatment with -adrenergic receptor antagonists
prevented cardiomyocyte apoptosis in mice (31). These observations
suggest that -adrenergic stimulation may induce deterioration of
cardiac function by inducing cardiomyocyte apoptosis during the
development of heart failure. Stimulation of -adrenergic receptors
activates adenylate cyclase, which increases intracellular cAMP. The
cAMP-dependent protein kinase A activates L-type
Ca2+ channels, leading to a significant increase in
cytosolic Ca2+ levels. In the present study, Iso increased
the number of TUNEL-positive cells. A calcium ionophore, ionomycin,
which causes a sustained increase in intracellular Ca2+
concentration, increased the number of TUNEL-positive cells as much as did maximum Iso stimulation. Pretreatment with the
L-type Ca2+ channel antagonist nifedipine and the selective
calcineurin inhibitors CsA and FK506 strongly inhibited the Iso-induced
increase in TUNEL-positive cells and Iso-induced DNA ladder formation.
Taken together, these results suggest that the
Ca2+-calcineurin pathway plays a critical role in
-adrenergic receptor-induced cardiomyocyte apoptosis.
The Bcl-2 family proteins are important regulators of cell death in
mammalian cells. Apoptosis is determined by the relative balance
between proapoptotic molecules such as Bad and Bax and antiapoptotic
molecules such as Bcl-2 and Bcl-xL. Phosphorylated Bad is sequestered
in the cytosol by 14-3-3 proteins and is inactivated, thus
promoting cell survival. Dephosphorylated Bad promotes cell death at least in part through heterodimerization with the
antiapoptotic proteins Bcl-2 and Bcl-xL. The present study demonstrated
that Iso as well as a calcium ionophore transiently reduced
phosphorylation levels of Bad and that Iso-induced dephosphorylation of
Bad was abolished when the Ca2+-calcineurin pathway was
inhibited by calcineurin inhibitors and an L-type Ca2+
channel antagonist. Furthermore, we examined the subcellular distribution of cytochrome c in cardiomyocytes in the
presence or absence of Iso. Iso significantly induced the release of
cytochrome c from mitochondria to the cytosol, and the
Iso-induced release of cytochrome c was reduced by
pretreatment with calcineurin inhibitors. Bcl-2 and Bcl-xL function in
the mitochondrial membrane as antiapoptotic molecules by preventing the
release of cytochrome c from mitochondria (24, 25). When Bad
is dephosphorylated and translocated from the cytosol to mitochondria,
Bad has been reported to form a complex with Bcl-2 and induce the
release of cytochrome c (14). These results and observations
collectively suggest that calcineurin plays an important role in the
Iso-induced release of cytochrome c from mitochondria to the
cytosol, possibly through dephosphorylating Bad in cardiac myocytes.
It has been reported that the calcineurin inhibitors prevent the
development of cardiac hypertrophy and cardiomyopathy in rodent models
(32). In the present study, to elucidate whether calcineurin is
involved in the apoptosis of cardiac myocytes in vivo, we
generated dn calcineurin transgenic mice under the control of cardiac
myocyte-specific -myosin heavy chain promoter. It has been reported
that transfected CnA induces the redistribution of Bad from the
cytosol to mitochondria and the translocation of another calcineurin
substrate, nuclear factor of activated T cells, from the cytosol to the
nucleus. In contrast, dn calcineurin, a trans-dominant inhibitory
mutant of calcineurin, prevented the Ca2+-induced
redistribution of Bad and nuclear factor of activated T cells and
reduced apoptosis, indicating that dn calcineurin was effectively
suppressing endogenous calcineurin function (14). Infusion of Iso
increased the calcineurin activity and the number of TUNEL-positive
cells in the heart. Iso-induced increases in the number of
TUNEL-positive cells as well as in calcineurin activity were
significantly less in the hearts of the transgenic mice or FK506-treated mice than in the hearts of wild-type mice. These results
suggest that stimulation of -adrenergic receptors also induces
cardiomyocyte apoptosis through calcineurin in vivo.
Our results collectively suggest that the Ca2+-calcineurin
pathway plays a critical role in the progression of heart failure by
regulating cardiomyocyte apoptosis and that inhibition of the Ca2+-calcineurin pathway may be effective in the treatment
of heart failure. To the contrary, De Windt et al. (33)
recently reported that calcineurin activation prevents apoptosis of
cardiac myocytes and that calcineurin transgenic mice hearts
significantly increased TUNEL-positive cells of non-cardiomyocytes but
not of cardiomyocytes. The reason for the discrepancy is unknown at
present; however, it may come from the different stimuli. De Windt
et al. (33) have reported that the activation of
calcineurin protects cardiomyocytes against apoptosis induced by
2-deoxyglucose and staurosporine in vitro and by
ischemia/reperfusion in vivo. We also observed that
ischemia/reperfusion induced more apoptosis in the hearts of
transgenic mice expressing dn calcineurin than in the hearts of
wild-type mice.2 It has been
reported that calcineurin can activate opposing pathways that either
suppress or induce apoptosis in the same cells (34). Further studies
are necessary to elucidate in what situations calcineurin induces or
suppresses cardiomyocyte apoptosis.
 |
FOOTNOTES |
*
This work was supported by a grant-in-aid for scientific
research, Development of Scientific Research on Priority Areas
from the Ministry of Education, Science, Sports, and Culture of Japan and by the Program for Promotion of Fundamental Studies in Health Sciences of the Organization for Drug ADR Relief, R&D Promotion, and Product Review of Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom all correspondence should be addressed: Dept. of Medicine
III, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-Ku, Chiba
260-8677, Japan. Tel.: 81-43-222-7171 (ext. 5264); Fax: 81-43-226-2096;
E-mail: komuro-tky@umin.ac.jp.
Published, JBC Papers in Press, August 7, 2000, DOI 10.1074/jbc.M002844200
2
Y. Zou and I. Komuro, unpublished observation.
 |
ABBREVIATIONS |
The abbreviations used are:
Iso, isoproterenol;
TUNEL, terminal deoxynucleotide transferase-mediated dUTP nick end
labeling;
dn, dominant negative;
CnA, calcineurin A;
CsA, cyclosporin
A.
 |
REFERENCES |
| 1.
|
Narula, J. N.,
Haider, N.,
Virmani, R.,
DiSalvo, T. G.,
Kolodgie, F. D.,
Hajjar, R. J.,
Schmidt, U.,
Semigran, M. J.,
Dec, G. W.,
and Khaw, B. A.
(1996)
N. Engl. J. Med.
335,
1182-1189
|
| 2.
|
Olivetti, G.,
Abbi, R.,
Quaini, F.,
Kajstura, J.,
Cheng, W.,
Nitahara, J. A.,
Quaini, E.,
Di Loreto, C.,
Beltrami, C. A.,
Krajewski, S.,
Reed, J. C.,
and Anversa, P.
(1997)
N. Engl. J. Med.
336,
1131-1141
|
| 3.
|
Saraste, A.,
Pulkki, K.,
Kallajoki, M.,
Henriksen, K.,
Parvinen, K. M.,
and Voipio-Plukki, L. M.
(1997)
Circulation
95,
320-323
|
| 4.
|
Leri, A.,
Claudio, P. P.,
Li, Q.,
Wang, X.,
Reiss, K.,
Wang, S.,
Malhotra, A.,
Kajstura, J.,
and Anversa, P.
(1998)
J. Clin. Invest.
101,
1326-1342
|
| 5.
|
Krown, K. A.,
Page, M. T.,
Nguyen, C.,
Zechner, D.,
Gutierrez, V.,
Comstock, K. L.,
Glembotski, C. C.,
Quintana, P. J.,
and Sabbadini, R. A.
(1996)
J. Clin. Invest.
98,
2854-2865
|
| 6.
|
Aikawa, R.,
Komuro, I.,
Yamazaki, T.,
Zou, Y.,
Kudoh, S.,
Tanaka, M.,
Siojima, I.,
Hiroi, Y.,
and Yazaki, Y.
(1997)
J. Clin. Invest.
100,
1813-1821
|
| 7.
|
Hasking, G. J.,
Esler, M. D.,
Jennings, G.,
Burton, D.,
Johns, J. A.,
and Korner, P. I.
(1986)
Circulation
73,
615-621
|
| 8.
|
Communal, C.,
Singh, K.,
Pimentel, D. R.,
and Colucci, W. S.
(1998)
Circulation
98,
1329-1334
|
| 9.
|
Iwai-Knai, E.,
Hasegawa, K.,
Araki, M.,
Kakita, T.,
Morimoto, T.,
and Sasayama, S.
(1999)
Circulation
100,
305-311
|
| 10.
|
Shizukuda, Y.,
Buttrick, P. M.,
Geenen, D. L.,
Borczuk, A. C.,
Kitsis, R. N.,
and Sonnenblick, E. D.
(1998)
Am. J. Physiol.
275,
H961-H968
|
| 11.
|
Geng, Y.,
Ishikawa, Y.,
Vatner, D. E.,
Wagner, T. E.,
Bishop, S. P.,
Vatner, S. F.,
and Homcy, C. J.
(1999)
Circ. Res.
84,
34-42
|
| 12.
|
Shibasaki, F.,
and McKeon, F.
(1995)
J. Cell Biol.
131,
735-743
|
| 13.
|
Ankarcrona, M.,
Dypbukt, J. M.,
Orrenius, S.,
and Nicotera, P.
(1996)
FEBS Lett.
394,
321-324
|
| 14.
|
Wang, H.,
Pathan, N.,
Ethell, I. M.,
Krajewski, S.,
Yamaguchi, Y.,
Shibasaki, F.,
McKeon, F.,
Bobo, T.,
Franke, T. F.,
and Reed, J. C.
(1999)
Science
284,
339-343
|
| 15.
|
Molkentin, J. D.,
Lu, J. R.,
Antos, C. L.,
Markham, B.,
Richardson, J.,
Robbins, J.,
Grant, S. R.,
and Olson, E. N.
(1998)
Cell
93,
215-228
|
| 16.
|
Simpson, P.
(1983)
J. Clin. Invest.
72,
732-738
|
| 17.
|
Bean, B. P.,
Nowycky, M. C.,
and Tisen, R. W.
(1984)
Nature
307,
371-375
|
| 18.
|
Sheu, S. S.,
Sharma, V. K.,
and Korth, M.
(1987)
Am. J. Physiol.
252,
H697-H703
|
| 19.
|
Zha, J.,
Harada, H.,
Yang, E.,
Jockel, J.,
and Krosmeyer, S. J.
(1996)
Cell
87,
619-628
|
| 20.
|
del Peso, L.,
Gonzalez-Garcia, M.,
Page, C.,
Herrera, R.,
and Nunez, G.
(1997)
Science
278,
687-689
|
| 21.
|
Scheid, M.,
and Duronio, V.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7439-7444
|
| 22.
|
Craddock, B. L.,
Orchiston, E. A.,
Hinton, H. J.,
and Welham, M. J.
(1999)
J. Biol. Chem.
274,
10633-10640
|
| 23.
|
Reed, J. C.
(1997)
Cell
91,
559-562
|
| 24.
|
Yang, J.,
Liu, X.,
Bhalla, K.,
Kim, C. N.,
Ibrado, A. M.,
Cai, J.,
Peng, T. I.,
Jones, D. P.,
and Wang, X.
(1997)
Science
275,
1129-1132
|
| 25.
|
Kluck, R. M.,
Bossy-Wetzel, E.,
Green, D. R.,
and Newmeyer, D. D.
(1997)
Science
275,
1132-1136
|
| 26.
|
Swedberg, K.,
Viquerat, C.,
Rouleau, J. L.,
Roizen, M.,
Atherton, B.,
Parmley, W. W.,
and Chatterjee, K.
(1984)
Am. J. Cardiol.
54,
783-786
|
| 27.
|
Rona, G.
(1985)
J. Mol. Cell. Cardiol.
17,
291-306
|
| 28.
|
Doughty, R. N.,
McMahon, S.,
and Sharpe, N.
(1994)
J. Am. Coll. Cardiol.
23,
814-821
|
| 29.
|
Newton, G. E.,
and Parker, J. D.
(1996)
Circulation
94,
353-358
|
| 30.
|
Yoshikawa, T.,
Handa, S.,
Anzai, T.,
Nishimura, H.,
Baba, A.,
Akaisi, M.,
Mitamura, H.,
and Ogawa, S.
(1996)
Am. Heart J.
131,
329-336
|
| 31.
|
Asai, K.,
Yang, G. P.,
Geng, Y. J.,
Takagi, G.,
Bishop, S.,
Ishikawa, Y.,
Shannon, R. P.,
Wagner, T. E.,
Vatner, D. E.,
Homcy, C. J.,
and Vatner, S. F.
(1999)
J. Clin. Invest.
104,
551-558
|
| 32.
|
Sussman, M. A.,
Lim, H. W.,
Gude, N.,
Taigen, T.,
Olson, E. N.,
Robbins, J.,
Colbert, M. C.,
Gualberto, A.,
Wieczorek, D. F.,
and Molkentin, J. D.
(1998)
Science
281,
1690-1693
|
| 33.
|
De Windt, L. J.,
Lim, H. W.,
Taigen, T.,
Wencker, D.,
Condorelli, G.,
Dorn, G. W., II,
Kitsis, R. N.,
and Molkentin, J. D.
(2000)
Circ. Res.
86,
255-263
|
| 34.
|
Lotem, J.,
Kama, R.,
and Sachs, L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
12016-12020
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
W.-Q. Tan, J.-X. Wang, Z.-Q. Lin, Y.-R. Li, Y. Lin, and P.-F. Li
Novel Cardiac Apoptotic Pathway: The Dephosphorylation of Apoptosis Repressor With Caspase Recruitment Domain by Calcineurin
Circulation,
November 25, 2008;
118(22):
2268 - 2276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Sama, D. M. Mathis, J. L. Furman, H. M. Abdul, I. A. Artiushin, S. D. Kraner, and C. M. Norris
Interleukin-1{beta}-dependent Signaling between Astrocytes and Neurons Depends Critically on Astrocytic Calcineurin/NFAT Activity
J. Biol. Chem.,
August 8, 2008;
283(32):
21953 - 21964.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Zhang, A. Knapton, S. E. Lipshultz, J. L. Weaver, and E. H. Herman
Isoproterenol-induced Cardiotoxicity in Sprague-Dawley Rats: Correlation of Reversible and Irreversible Myocardial Injury with Release of Cardiac Troponin T and Roles of iNOS in Myocardial Injury
Toxicol Pathol,
February 1, 2008;
36(2):
277 - 278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ogino, G. Takemura, H. Kanamori, H. Okada, R. Maruyama, S. Miyata, M. Esaki, M. Nakagawa, T. Aoyama, H. Ushikoshi, et al.
Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling
Am J Physiol Heart Circ Physiol,
October 1, 2007;
293(4):
H2271 - H2280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Parsons, D. P. Millay, M. A. Sargent, F. J. Naya, E. M. McNally, H. L. Sweeney, and J. D. Molkentin
Genetic Disruption of Calcineurin Improves Skeletal Muscle Pathology and Cardiac Disease in a Mouse Model of Limb-Girdle Muscular Dystrophy
J. Biol. Chem.,
March 30, 2007;
282(13):
10068 - 10078.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Fielitz, E. van Rooij, J. A. Spencer, J. M. Shelton, S. Latif, R. van der Nagel, S. Bezprozvannaya, L. de Windt, J. A. Richardson, R. Bassel-Duby, et al.
Loss of muscle-specific RING-finger 3 predisposes the heart to cardiac rupture after myocardial infarction
PNAS,
March 13, 2007;
104(11):
4377 - 4382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. M. Fischer, C. S. Cox Jr., G. A. Laine, U. Mehlhorn, W. Bloch, and S. J. Allen
Induction of cardioplegic arrest immediately activates the myocardial apoptosis signal pathway
Am J Physiol Heart Circ Physiol,
March 1, 2007;
292(3):
H1630 - H1633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Suzuki, E. Bayna, H. L. Li, E. D. Molle, and W. Y.W. Lew
Lipopolysaccharide Activates Calcineurin in Ventricular Myocytes
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
491 - 499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, J. S. Heuser, L. C. Cunningham, S. D. Kosanke, and M. W. Cunningham
Mimicry and Antibody-Mediated Cell Signaling in Autoimmune Myocarditis
J. Immunol.,
December 1, 2006;
177(11):
8234 - 8240.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Liu, B. J. Wilkins, Y. J. Lee, H. Ichijo, and J. D. Molkentin
Direct Interaction and Reciprocal Regulation between ASK1 and Calcineurin-NFAT Control Cardiomyocyte Death and Growth
Mol. Cell. Biol.,
May 15, 2006;
26(10):
3785 - 3797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Maruyama, G. Takemura, N. Tohse, T. Ohkusa, Y. Ikeda, K. Tsuchiya, S. Minatoguchi, M. Matsuzaki, T. Fujiwara, and H. Fujiwara
Synchronous progression of calcium transient-dependent beating and sarcomere destruction in apoptotic adult cardiomyocytes
Am J Physiol Heart Circ Physiol,
April 1, 2006;
290(4):
H1493 - H1502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nagy, V. Champattanachai, R. B. Marchase, and J. C. Chatham
Glucosamine inhibits angiotensin II-induced cytoplasmic Ca2+ elevation in neonatal cardiomyocytes via protein-associated O-linked N-acetylglucosamine
Am J Physiol Cell Physiol,
January 1, 2006;
290(1):
C57 - C65.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Chen, X. Zhang, H. Kubo, D. M. Harris, G. D. Mills, J. Moyer, R. Berretta, S. T. Potts, J. D. Marsh, and S. R. Houser
Ca2+ Influx-Induced Sarcoplasmic Reticulum Ca2+ Overload Causes Mitochondrial-Dependent Apoptosis in Ventricular Myocytes
Circ. Res.,
November 11, 2005;
97(10):
1009 - 1017.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G Burniston, A. Saini, L.-B. Tan, and D. F Goldspink
Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat
Exp Physiol,
September 1, 2005;
90(5):
755 - 761.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Nakajima-Takenaka, S. Sakata, S. Kato, Y. Ohga, K.-y. Murata, S. Taniguchi, and M. Takaki
Detrimental effects after dobutamine infusion on rat left ventricular function: mechanical work and energetics
Exp Physiol,
July 1, 2005;
90(4):
635 - 644.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nathan, I. Friehs, Y.-H. Choi, D. B. Cowan, H. Cao-Danh, F. X. McGowan, and P. J. del Nido
Cyclosporin A But Not FK-506 Protects Against Dopamine-Induced Apoptosis in the Stunned Heart
Ann. Thorac. Surg.,
May 1, 2005;
79(5):
1620 - 1626.
[Abstract]
[Full Text]
[PDF]
|
|